Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (377)	9/24/2007 8:33:25 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 384

Great news to lie awake all night waiting for it................ouch! So much for management keeping lid on data..........this was a total disaster! I guess a name change will be coming soon!!! Fail with one, merely change name and start the next sure thing! Sonus is long gonus!

To: tuck who wrote (377)	9/24/2007 8:35:01 AM
From: tuck	Read Replies (1) \| Respond to of 384

CC notes Company noting that the formulation for TOCOSOL Camptothecin involves a different Vitamin E formulation; as such cannot draw conclusions about it from the failed TOCOSOL Paclitaxel trial. Obviously, the market assigns the former negative value, as the stock is trading for 1/2 cash, premarket. One can expect the company to soldier on with TOCOSOL Camptothecin. They said that so far in the P!, they are seeing greater half life and patient exposure to the drug. They said that trial was enrolling a little more slowly than they hoped. It'll probably enroll even more slowly now. Nevertheless, they expect data by the end of the year. They have no idea if they failed the drug or the drug failed them, to paraphrase the CEO. They have not yet done a country by country analysis. They expect to have the data more fully reviewed for an update on their quarterly call in November. Tuck